Drug Combination Details
| General Information of the Combination (ID: C07401) | |||||
|---|---|---|---|---|---|
| Name | Costunolide NP Info | + | Ionizing radiation Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | CDK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | MPIP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | RAD53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HA22T/VGH | CVCL_7046 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. Radiat Oncol. 2011 May 30;6:56. | |||
